Company / Shareholders' Equity
Sarepta Therapeutics Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$1.1B
FY2025
5-year range
$761.8M / $1.5B
FY2021-FY2025
Trend
-25.3%
vs FY2024
Sector context
#42 of 213
Health Care
What the data says
Sarepta Therapeutics's shareholders' equity of $1.1B is higher than 80% of companies in the Health Care sector (FY2025). Shareholders' Equity has fluctuated over the past 10 years, ranging from $337M in FY2016 to $1.5B in FY2024.
Based on SEC 10-K filings.
$1.1B in FY2025 with a 5-year CAGR of +2.0%. Top quartile in the Health Care sector.
Improved from $859M to $1.1B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +14.4%
- 5-Year CAGR
- +2.0%
- 10-Year CAGR
- -
Sector benchmark
-55.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +2.0%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 25.3% year-over-year.
- Ranks #42 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1B | -25.3% |
| FY2024 | $1.5B | +77.8% |
| FY2023 | $859.3M | +12.8% |
| FY2022 | $761.8M | -17.9% |
| FY2021 | $928.0M | -10.1% |
| FY2020 | $1.0B | +30.8% |
| FY2019 | $789.2M | -23.5% |
| FY2018 | $1.0B | +30.8% |
| FY2017 | $789.2M | +134.4% |
| FY2016 | $336.7M | +76.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026